Bruno Vellas
Ratings
0
Nobody has rated this yet. Be the first!
Works
3
Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease
Measuring Global Brain Atrophy with the Brain Volume/Cerebrospinal Fluid Index: Normative Values, Cut-Offs and Clinical Associations
A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease
